Echogenicity of the substantia nigra in patients with de Novo Parkinson's disease. Relationship with parkinsonian phenotypes. (P6.062)

INTRODUCTION: Currently it is considered that the substantia nigra hyperechogenicity (SNH) is a marker of susceptibility of nigrostriatal system. The recognition of different clinical subtypes of PD may be associated with different pathophysiologic mechanisms or the involvement of different anatomical regions. The international literature is not conclusive on SNH differences between the different parkinsonian phenotypes. OBJECTIVES: Determining the presence of SNH in Transcranial Ultrasound (TCU) of de novo PD patients and assess potential differences between PD phenotypes and their relationship with baseline cognitive status. MATERIAL AND METHODS: We evaluated the results of the TCU in a cohort of patients with de novo PD. They were divided into three clinical phenotypes: Tremorigenic (Fen-T); Rigid Akinetic (Fen-RA); Mixed (Fen-M). We consider age, sex, duration and, stage of disease, motor and cognitive impairment. RESULTS: From a total of 89 de novo PD patients, 9 were excluded: lack of window 5, study unrealized 4. Total number of patients analyzed: 80. Average time evolution: 12 months . Average age: 68 years. The Hoehn and Yahr stage and MDS-UPDRS III score was significantly higher in the Fen-RA (p <0.001). Cognitive impairment was also greater in this group (p 0.03). The HSN was present in 49 patients (61.2[percnt]). SNH phenotypes: Fen-T: 27 (55[percnt]), unilateral: 13 (48[percnt]), bilateral: 14 (51[percnt]) Fen-RA: 12 (24[percnt]), unilateral: 3 (25[percnt]), bilateral: 9 (75[percnt]) Fen-M: 10 (20[percnt]), unilateral: 5 (50[percnt]), bilateral: 5 (50[percnt]) There was no significant difference in laterality between the different phenotypes. CONCLUSION: The presence of SNH in our de novo PD population was lower than those reported in the literature. There were no statistically significant differences in the presence or laterality of SNH between different PD phenotypes, or in patients with or without cognitive impairment. Disclosure: Dr. bestoso has nothing to disclose.